Toward a Multi-Trait Genetic Panel Targeting Training, Rehabilitation, and Chronic Disease Prevention: A Narrative Review
Imperatore A., Mennitti C., De Fonzo G., Amitrano R., Gentile A., Calvanese M.
Narrative Review, published in Genes (Basel) (2025) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- Genes (Basel) (2025)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 41300761
- PMCID
- PMC12652476
- DOI
- 10.3390/genes16111309
- Citations
- 1
Abstract (original English)
Athletic performance results from complex interactions between genetic and environmental factors. This review compiles and synthesizes available literature on polymorphic genes associated with endurance, power, and strength performance, as well as their links to injury susceptibility and chronic metabolic diseases. Endurance performance is modulated by ACE , PPARGC1A , HFE , UCP2 , UCP3 , CDKN1A , and PPARA , regulating mitochondrial biogenesis, oxygen utilization, and muscle fiber composition. Power performance involves ACTN3 , MCT1 , IGF1 , AMPD1 , AGT , and AGTR2 , affecting anaerobic metabolism, lactate clearance, and fast-twitch fiber recruitment. Strength performance is influenced by AR , PPARG , ARK2N , MMS22L , LRPPRC , PHACTR1 , and MTHFR , related to androgen signaling, muscle hypertrophy, and recovery. Injury-related genes ( COL1A1 , COL5A1 , IL6 , VEGFA , NOG ) and metabolic risk genes ( FTO , PPARG , ADRB3 ) further highlight the clinical relevance of genomics. Collectively, these insights support the application of genetic information to personalize training, enhance performance, prevent injuries, and guide exercise interventions to mitigate metabolic disease risk.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.